Genentech (South San Francisco, a member of the Roche Group since 2009) is one of the most active large-pharma buyers of externally-discovered peptide and biologic assets, and its August 2026 news cycle has been dominated by two large business-development moves plus continued advancement of the autogene cevumeran pancreatic cancer vaccine.
On Monday August 24, 2026, Genentech signed an exclusive licensing agreement with Hanmi Pharm (KRX: 128940) for HM17321, a proprietary urocortin-2 (UCN2) analog peptide that selectively activates the corticotropin-releasing factor 2 receptor (CRFR2) for obesity — a mechanism distinct from every currently-approved GLP-1 or incretin-based obesity drug and positioned to preserve lean body mass. Terms: $190 million upfront plus up to $2.3 billion in development, regulatory, and commercial milestones plus tiered royalties. Genentech assumes control from Phase 2 forward. On Friday August 28, 2026, DualityBio announced a global collaboration and license agreement with Genentech to develop next-generation antibody-drug conjugates on the DUPAC (DualityBio Unique Payload Antibody Conjugate) novel-payload platform: $45 million upfront plus more than $1 billion in aggregate milestones, plus tiered royalties. The DUPAC platform targets payloads with novel mechanisms of action designed to address resistance to existing topoisomerase inhibitor-based ADCs.
Autogene cevumeran, the individualized long-peptide neoantigen vaccine co-developed with BioNTech, continues to define the pancreatic cancer immunotherapy category with long-term survival follow-up. Stories here cover Genentech's peptide licensing, ADC alliances, and the ongoing vaccine program. See [[roche]], [[dualitybio]], and [[hanmi]] for adjacent threads.
DualityBio (HKEX: 9606) announced Friday August 28, 2026 a global collaboration and license agreement with Genentech (Roche Group) to develop next-generation antibody-drug conjugates on DualityBio's proprietary DUPAC (DualityBio Unique Payload Antibody Conjugate) platform. Terms: $45 million upfront to DualityBio plus more than $1 billion in aggregate development, regulatory, and commercial milestone payments across all programs, with tiered royalties on annual net sales. DualityBio handles discovery through Phase Ia; Genentech takes over global clinical development and commercialization. The DUPAC platform is one of DualityBio's four proprietary ADC platforms and is dedicated to payloads with novel mechanisms of action designed to address resistance to existing topoisomerase inhibitor-based ADCs (Trodelvy, Enhertu, Datroway, and successors). The deal is Genentech's second Asia-based ADC alliance in a week and continues the pattern of large pharma buying diverse payload chemistries as ADC-first-line combinations expand.
Follow-through analyst commentary Tuesday August 25, 2026 on the Monday Roche (SIX: ROG) and Hanmi Pharm HM17321 urocortin-2 (UCN2) obesity licensing deal positioned Roche as now targeting a top-three global obesity commercial position behind Eli Lilly (Zepbound, Mounjaro, Foundayo, and upcoming retatrutide) and Novo Nordisk (Wegovy, Ozempic, Wegovy Pill, Wegovy HD, CagriSema under review). Deal recap: $190 million upfront, up to $2.3 billion in milestones, plus tiered royalties; Genentech gets global rights excluding South Korea. HM17321 mechanism: a proprietary urocortin-2 (UCN2) analog peptide that selectively activates the corticotropin-releasing factor 2 receptor (CRFR2), a mechanism distinct from the incretin pathway (GLP-1, GIP) that anchors every currently-approved obesity drug. Roche obesity portfolio positioning: HM17321 combines with Roche's existing CT-388 (a dual GIP/GLP-1 receptor agonist acquired in the December 2023 Carmot Therapeutics acquisition for $2.7 billion, currently in Phase 2 for obesity and type 2 diabetes) and the emerging Roche obesity pipeline including RG7500 orforglipron precursor and other early-stage assets. The multi-mechanism portfolio provides a differentiated commercial positioning to compete across weight-loss efficacy (Roche's incretin agonist candidates match Lilly and Novo) and muscle-preservation (HM17321's differentiated UCN2 mechanism designed for lean mass preservation). Roche's obesity ambition contrasts with prior investor skepticism about its late-cycle entry into the category; Tuesday's analyst commentary suggests the multi-mechanism strategy could position Roche credibly for 2028-2030 commercial launches assuming pipeline programs advance to registration.
Hanmi Pharm (KRX: 128940) signed Monday August 24, 2026 an exclusive licensing agreement with Genentech (a member of the Roche Group) for HM17321, a proprietary urocortin-2 (UCN2) analog peptide for obesity. Deal terms: $190 million upfront payment, up to $2.3 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on sales. Territory: Genentech secures global rights excluding South Korea, where Hanmi retains the license. Mechanism: HM17321 selectively activates the corticotropin-releasing factor 2 receptor (CRFR2), a peptide-hormone receptor pathway distinct from the incretin pathway (GLP-1 receptor, GIP receptor) that anchors every currently-approved obesity drug including semaglutide, tirzepatide, orforglipron, and the broader GLP-1 receptor agonist class. Urocortin-2 is a naturally occurring 38-amino-acid peptide of the corticotropin-releasing factor family. Differentiated profile: HM17321 is positioned as a potential first-in-class treatment designed to simultaneously promote weight loss and preserve lean body mass, an important differentiator against the semaglutide-tirzepatide-retatrutide GLP-1 class where roughly 25% of the total weight lost is lean muscle mass. Development pathway: Hanmi received FDA IND clearance to initiate a Phase 1 clinical trial in November 2025. Hanmi is responsible for completing the Phase 1 clinical trial, after which Genentech will take over development starting with Phase 2 clinical trials. The deal represents one of the largest 2026 obesity licensing transactions and adds a substantially different mechanism to Roche's obesity portfolio that also includes CT-388 (dual GIP/GLP-1 agonist from the Carmot Therapeutics acquisition).
PeptiDream Inc. (TSE: 4587), the Kawasaki-based peptide discovery platform company, announced the appointment of three new Executive Vice Presidents. The leadership restructure accompanies the company's multi-year deal-book growth and the increasing preclinical-to-clinical progression of its partnered peptide programs. Company background: PeptiDream operates the Peptide Discovery Platform System (PDPS), a proprietary technology for designing constrained cyclic peptides. PDPS uses genetic-code reprogramming to generate trillion-scale diverse libraries of non-standard peptides (containing modified amino acids not found in natural proteins), which are then screened to identify molecules that bind target proteins with high affinity and specificity. Applications span oncology (peptide-drug conjugates, radioligand-conjugated peptides), immunology (novel immune-modulating peptides), and rare disease peptide drug development. Partnership book: PeptiDream has active collaborations with Novartis (multiple targets), Merck (peptide-radioligand programs), Genentech/Roche (immuno-oncology), AbbVie (multiple targets), Bristol Myers Squibb, Eli Lilly (including the recent obesity-adjacent partnership), and multiple mid-cap biopharmaceutical companies. The constrained cyclic peptide modality PeptiDream specializes in sits between traditional linear peptides (subject to protease degradation and short half-lives) and small-molecule drugs (limited target diversity), and has grown as a distinct drug modality throughout the 2020s as GLP-1 and other peptide successes have expanded the industry's willingness to invest in peptide chemistry platforms.
Genentech presented Phase 2 CT388-103 data for enicepatide, the once-weekly GLP-1/GIP dual agonist, at the Roche investor event Monday June 8. The 48-week study produced 22.5% placebo-adjusted weight loss in adults with overweight or obesity, with 26% of participants losing more than 30% of body weight and almost 40% reaching at least 25%. Both enicepatide and petrelintide advance into Phase 3, and the planned Phase 2 multi-arm fixed-dose combination of the two starts mid-2026.
Genentech confirmed at its Monday investor event that the planned Phase 2 multi-arm fixed-dose combination of petrelintide (amylin analog) and enicepatide (GLP-1/GIP) starts mid-2026. The setup mirrors Novo's CagriSema and Lilly's Mounjaro-plus-amylin work, with Roche aiming for the same dual-mechanism economics that produced REIMAGINE 2's head-to-head win this week. Roche projected $9 billion in peak annual sales for the combined obesity pipeline at its Q1 print.
Genentech, Roche's US arm, will present detailed Phase 2 ZUPREME-1 data for the amylin analog petrelintide and Phase 2 CT388-103 data for the GLP-1/GIP agonist enicepatide as late-breakers at ADA 2026, with a June 8 virtual investor event. The Roche obesity package combines the two peptides as a planned fixed-dose Phase 2 combination later this year, and the company has projected $9 billion in peak annual sales for the combined pipeline.
Nearly half of participants in a Phase 1 trial of BioNTech/Genentech's personalized mRNA neoantigen vaccine autogene cevumeran remain alive up to six years after treatment, with T-cell responses showing no signs of waning. Eight of 16 patients produced durable CD8+ T cells targeting tumor neoantigens after nine doses, with the immune memory still detectable at six-year follow-up. A Phase 2 trial is underway.